Core Insights - Tianyu Bio was established in June 2000 and listed on the Shanghai Stock Exchange in March 2017, focusing on ecological environment governance with technical advantages in ecological restoration and landscaping [1] Financial Performance - For Q3 2025, Tianyu Bio reported revenue of 536 million yuan, ranking 12th among 12 companies in the industry, while the top company, Muyuan Foods, achieved revenue of 111.79 billion yuan [2] - The net profit for the same period was 10.67 million yuan, placing the company 10th in the industry, with the leading company, Wen's Foodstuffs, reporting a net profit of 5.42 billion yuan [2] Financial Ratios - As of Q3 2025, Tianyu Bio's debt-to-asset ratio was 76.41%, higher than the previous year's 73.16% and above the industry average of 57.82%, indicating significant debt pressure [3] - The gross profit margin for Q3 2025 was 13.16%, down from 19.74% year-on-year and below the industry average of 14.00%, suggesting a need for improvement in profitability [3] Executive Compensation - The chairman, Luo Weiguo, received a salary of 352,000 yuan in 2024, a decrease of 90,000 yuan from 2023 [4] - The president, Meng Zhuowei, earned 409,100 yuan in 2024, down by 91,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.49% to 21,700, while the average number of circulating A-shares held per shareholder decreased by 6.97% to 13,400 [5]

Core Points - The aquaculture sector experienced a decline of 1.31% on October 30, with Tianyu Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Yisheng Co. (002458) closed at 9.03, up 0.33% with a trading volume of 97,800 shares and a turnover of 88.43 million yuan [1] - Xiantan Co. (002746) closed at 6.31, up 0.32% with a trading volume of 154,800 shares and a turnover of 97.81 million yuan [1] - Tianyu Biology (603717) closed at 8.73, down 3.64% with a trading volume of 155,200 shares and a turnover of 137 million yuan [2] - Huaying Agriculture (002321) closed at 2.77, down 3.15% with a trading volume of 424,400 shares and a turnover of 119 million yuan [2] Capital Flow - The aquaculture sector saw a net outflow of 188 million yuan from institutional investors, while retail investors had a net inflow of 141 million yuan [2] - The main capital inflow and outflow for specific stocks included: - Jingji Zhinnong (000048) had a net inflow of 19.99 million yuan from main capital [3] - Wens Foodstuff Group (300498) had a net inflow of 7.96 million yuan from main capital [3] - Yisheng Co. (002458) had a net inflow of 3.79 million yuan from main capital [3]

Core Viewpoint - Tianyu Biological (603717.SH) reported a significant decline in revenue and incurred losses in Q3 2025 compared to the previous year [1] Financial Performance - The company achieved a revenue of 123 million yuan in Q3, representing a year-on-year decrease of 38.69% [1] - For the first three quarters, the total revenue was 536 million yuan, down 14.23% year-on-year [1] - The net loss for Q3 was 12.43 million yuan, while the net loss for the first three quarters was 1.61 million yuan [1]

Group 1 - Tianyu Biological reported a revenue of approximately 536 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 14.23% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 1.61 million yuan [1] - As of the report date, Tianyu Biological's market capitalization was 2.6 billion yuan [2] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2] - The technology sector is leading the market's transformation [2]

证券代码：603717 证券简称：天域生物 公告编号：2025-102 天域生物科技股份有限公司 关于继续开展商品期货套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 交易目的 | □获取投资收益 套期保值（合约类别：商品；□外汇；□其他：________） | | | --- | --- | --- | | | □其他：________ | | | 交易品种 | 仅限于生猪养殖业务经营相关的产成品和原材料（包括但不 | | | | 限于生猪、玉米、豆粕、豆油等） | | | 交易金额 | 预计动用的交易保证金和权利金 上限（单位：万元） | 5,000.00 | | | 预计任一交易日持有的最高合约 价值（单位：万元） | 25,500.00 | | 资金来源 | 自有资金 □借贷资金 □其他：___ | | | 交易期限 | 2025年10月31日至2026年10月30日 | | 交易主要情况 （三）资金来源 已履行的审议程序 经第五届董事会审计委员会第一次会议事前审议通过，公司 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-101 天域生物科技股份有限公司 (一)《2025 年第三季度报告》 具体内容详见公司于同日在上海证券交易所官方网站上发布的《2025 年第 三季度报告》。 表决结果：7 票同意、0 票反对、0 票弃权、0 票回避。 本议案已经第五届董事会审计委员会第一次会议事前审议通过。 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 天域生物科技股份有限公司（以下简称"公司"）第五届董事会第三次会议 （以下简称"本次会议"）通知于 2025 年 10 月 17 日以电子邮件方式发出，本 次会议于 2025 年 10 月 29 日上午 10:00 在公司会议室以现场结合通讯表决方式 召开。本次会议应到董事 7 人，实到董事 7 人。本次会议由公司董事长罗卫国先 生主持，公司部分高级管理人员列席会议。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《公司章 程》和《董事会议事规则》等相关规定，会议形成的决议合法、 ...

Financial Performance - The company's operating revenue for the third quarter was ¥123,298,080.72, a decrease of 38.69% compared to the same period last year[4] - The total profit for the quarter was -¥19,173,115.50, reflecting a decline of 254.11% year-on-year[4] - The net profit attributable to shareholders was -¥12,428,911.08, a significant decrease of 7,912.82% compared to the previous year[4] - The net profit excluding non-recurring gains and losses was -¥14,856,098.85, with a year-to-date decrease of 1,201.31%[4] - The basic earnings per share for the quarter was -¥0.043, a decrease of 178.47% compared to the same period last year[5] - The diluted earnings per share for the quarter was also -¥0.043, reflecting a similar decline of 178.47% year-on-year[5] - The weighted average return on equity was -2.43%, a decrease of 2.45 percentage points compared to the previous year[5] Assets and Liabilities - Total assets at the end of the quarter were ¥2,993,661,485.46, down 6.88% from the end of the previous year[5] - The equity attributable to shareholders was ¥517,715,741.11, a slight decrease of 0.20% compared to the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 2,287,335,577.61, compared to CNY 2,506,452,041.54 at the end of 2024, indicating a reduction of about 8.7%[19] - The total assets of the company decreased to CNY 2,993,661,485.46 as of September 30, 2025, down from CNY 3,214,984,288.09 at the end of 2024, indicating a decline of approximately 6.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date was ¥147,211,536.83, an increase of 39.90%[4] - The company's cash and cash equivalents decreased to CNY 145,924,090.03 as of September 30, 2025, from CNY 178,048,527.26 at the end of 2024, reflecting a decline of approximately 18.0%[17] - The total cash and cash equivalents at the end of the period decreased to CNY 78,681,406.32 from CNY 115,160,450.82, a decline of 31.7%[29] - The company experienced a net cash outflow from financing activities of CNY -101,406,021.68, compared to CNY -23,938,126.12 in the previous year[29] - The investment activities generated a net cash outflow of CNY -67,463,775.81, compared to CNY -61,213,199.64 in the same period last year[29] Shareholder Information - The company reported a total of 21,713,000 common shares outstanding at the end of the reporting period[12] - Major shareholder Luo Weiguo holds 37,251,829 shares, representing 12.84% of total shares, with 22,000,000 shares pledged and 14,375,524 shares frozen[12] - Major shareholder Shi Dongwei holds 32,338,800 shares, representing 11.15% of total shares, with 29,000,000 shares pledged and 3,181,856 shares frozen[12] - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd. holds 22,000,000 shares, representing 7.58% of total shares[12] - The company has undergone a change in actual control, with Luo Weiguo becoming the sole actual controller after the termination of the concerted action agreement with Shi Dongwei[14] - As of August 25, 2025, Shi Dongwei has irrevocably agreed to waive all voting rights associated with his 32,338,800 shares[14] - The report indicates that there are no significant changes in the shareholding structure of the top 10 shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders remains unchanged[14] Future Plans and Investments - The company plans to issue up to 71,028,297 A-shares to Shanghai Daoyun Asset Management Co., Ltd., raising a total of no more than CNY 465.2353 million, which will be used for working capital and debt repayment[15] - The company is in the process of issuing A-shares, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission[15] Research and Development - Research and development expenses rose to CNY 11,407,398.61, an increase of 72.5% compared to CNY 6,607,811.49 in the same period last year[24] Financial Expenses - The company reported a significant increase in financial expenses, totaling CNY 31,050,606.74, compared to CNY 9,137,237.34 in the previous year, marking a rise of 239.5%[24] Overall Performance - For the first three quarters of 2025, total operating revenue was CNY 535,601,036.79, down approximately 14.2% from CNY 624,472,530.50 in the same period of 2024[22] - Total operating costs for the first three quarters of 2025 were CNY 567,048,150.94, a decrease of about 4.7% compared to CNY 594,720,864.52 in the previous year[22] - The net profit for the first three quarters of 2025 is CNY 10,668,058.84, a decrease of 60.9% compared to CNY 27,281,131.61 in the same period of 2024[24] - The total revenue from operating activities for the first three quarters of 2025 is CNY 765,216,638.76, down from CNY 834,739,497.39 in 2024, representing a decline of 8.3%[27] - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.0031, compared to CNY 0.0220 in the same period of 2024[24]

Core Viewpoint - Tianyu Bio reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its business operations [1] Financial Performance - The company's revenue for the third quarter was 123 million yuan, a year-on-year decrease of 38.69% [1] - The net profit for the third quarter showed a loss of 12.43 million yuan, representing a decline of 7,912.82% [1] - For the first three quarters, the total revenue was 536 million yuan, down 14.23% year-on-year [1] - The net profit for the first three quarters was a loss of 1.61 million yuan, which is a decline of 152.22% [1]

Core Viewpoint - Tianyu Biological (603717) announced that the company has no overdue guarantees [1] Summary by Relevant Sections - Company Announcement - Tianyu Biological confirmed in a recent announcement that there are no overdue guarantees [1]

累计担保情况 | 对外担保逾期的累计金额（万元） | / | | --- | --- | | 截至本公告日上市公司及其控股子 | | | 公司对外担保总额（万元） | 109,273.48 | | （实际发生的担保余额，不含本次） | | | 对外担保总额占上市公司最近一期 | 210.65 | | 经审计净资产的比例（%） | 对外担保总额超过最近一期经审计净资 | | 产 | 100% | | | □担保金额超过上市公司最近一期经审计 | | 特别风险提示（如有请勾选） | 净资产 50% | | | □对合并报表外单位担保金额达到或超过 | | | 最近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | 1 证券代码：603717 证券简称：天域生物 公告编号：2025-100 天域生物科技股份有限公司 关于公司 2025 年度对外担保预计的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 宜昌天域农牧 ...